Sernova Biotherapeutics (SVA) Q1 2025 earnings summary

Executive summary

• Report covers the three months ended January 31, 2025, with a corporate name change effective February 4, 2025.

• Focus remains on advancing the Cell Pouch platform for regenerative medicine and diabetes treatment.

Financial highlights

• Net loss for the quarter was $5,695,317, an improvement from $9,743,099 for the same quarter last year.

• Revenue not reported; operating expenses decreased to $4,800,260 from $10,027,682 year-over-year.

• Cash balance declined to $1,207,564 from $6,012,274 at October 31, 2024.

• Working capital deficit of $18,498,337 as of January 31, 2025.

• Accumulated deficit reached $156,054,459.

Outlook and guidance

• Material uncertainty exists regarding the ability to continue as a going concern; additional funding required before end of March 2025.

• Strategic financing initiatives are being pursued, including equity, loans, or alliances.

• Expects to incur further losses and negative cash flows in the foreseeable future.